齐拉西酮（CP-88059）是一种口服有效的非典型抗精神病药物，作为多巴胺D2受体（Ki=4.8 nM）和5-羟色胺5-HT2A（Ki=0.42 nM）、5-HT1A（Ki=3.4 nM）受体的拮抗剂，其对5-HT2A受体表现出最高的亲和力。
|
英文别名 (English Synonym) |
Ziprasidone |
|
中文名称 (Chinese Name) |
齐拉西酮 |
|
靶点 (Target) |
5-HT Receptor |
|
通路 (Pathway) |
Neuroscience |
|
CAS号 (CAS NO.) |
146939-27-7 |
|
分子式 (Formula) |
C21H21ClN4OS |
|
分子量 (Molecular Weight) |
412.94 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Su Z, Chen J, Martin RL, McDermott JS, Cox BF, Gopalakrishnan M, Gintant GA. Block of hERG channel by ziprasidone: biophysical properties and molecular determinants. Biochem Pharmacol. 2006 Jan 12;71(3):278-86. doi: 10.1016/j.bcp.2005.10.047. Epub 2005 Dec 1. PMID: 16325148.[2]Park S, Kim MS, Namkoong C, Park MH, Hong JP. The effect of ziprasidone on body weight and energy expenditure in female rats. Metabolism. 2012 Jun;61(6):787-93. doi: 10.1016/j.metabol.2011.10.011. Epub 2011 Dec 28. PMID: 22209671.
